{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Qiu X"],"funding":["the Donahue Family Fund","the H.L. Snyder Medical Research Foundation","The Prostate Cancer Foundation","the Institute for Prostate Cancer Research","the Cutler Family Fund for Prevention and Early Detection","The Fonds de Recherche du Québec – Santé","Canadian Institutes of Health","the Mayer Foundation","Craig Watjen Memorial Funds","NIH","Rebecca and Nathan Milikowsky Fund","CIHR","the Safeway Foundation","U.S. Department of Defense Prostate Cancer Research Program","nci","NCI","Doris Duke Charitable Foundation","NCI NIH HHS","Claudia Adams Barr Program for Innovative Cancer Research","Prostate Cancer Foundation","NIGMS NIH HHS","NIH HHS"],"pagination":["e157164"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9220831"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["7(10)"],"pubmed_abstract":["The androgen receptor (AR) is a master transcription factor that regulates prostate cancer (PC) development and progression. Inhibition of AR signaling by androgen deprivation is the first-line therapy with initial efficacy for advanced and recurrent PC. Paradoxically, supraphysiological levels of testosterone (SPT) also inhibit PC progression. However, as with any therapy, not all patients show a therapeutic benefit, and responses differ widely in magnitude and duration. In this study, we evaluated whether differences in the AR cistrome before treatment can distinguish between SPT-responding (R) and -nonresponding (NR) tumors. We provide the first preclinical evidence to our knowledge that SPT-R tumors exhibit a distinct AR cistrome when compared with SPT-NR tumors, indicating a different"],"journal":["JCI insight"],"pubmed_title":["Response to supraphysiological testosterone is predicted by a distinct androgen receptor cistrome."],"pmcid":["PMC9220831"],"funding_grant_id":["D.P.L. is a Lewis Katz – Young Investigator of the Prostate Cancer Foundation","P01 CA163227","Rebecca","Nathan Milikowsky Fund","the Mayer Foundation","Craig Watjen Memorial Funds","R01 CA251555","Early Detection","P01CA163227","R01GM107427,R01CA193910,R01CA251555,R01CA234715","R21CA194798","S10 OD028685","R01 CA193910","Claudia Adams Barr Program for Innovative Cancer Research","W81XWH-20-1-0111,W81XWH-21-1-0229,W81XWH-19-1-0565,W81XWH-18-1-0347,W81XWH-18-1-0354","the Cutler Family Fund for Prevention","D.P.L. is a Research Scholar – Junior 1","PNW Prostate Cancer SPORE P50CA097186","the Donahue Family Fund","Grant 2021184","the H.L. Snyder Medical Research Foundation","The Prostate Cancer Foundation","R01 GM107427","the Institute for Prostate Cancer Research","P50 CA097186","the Safeway Foundation","R01 CA234715","S10OD028685","R21 CA194798","PJT-162246"],"pubmed_authors":["Pomerantz M","Seo JH","Bell C","Hanratty B","Boufaied N","Feng FY","Abou Alaiwi S","Freedman ML","Qiu X","Long HW","Brown M","Haffner MC","Nguyen HM","Brown LG","Conner JL","Labbe DP","Nelson PS","O'Connor E","El Zarif T","Corey E"],"additional_accession":[]},"is_claimable":false,"name":"Response to supraphysiological testosterone is predicted by a distinct androgen receptor cistrome.","description":"The androgen receptor (AR) is a master transcription factor that regulates prostate cancer (PC) development and progression. Inhibition of AR signaling by androgen deprivation is the first-line therapy with initial efficacy for advanced and recurrent PC. Paradoxically, supraphysiological levels of testosterone (SPT) also inhibit PC progression. However, as with any therapy, not all patients show a therapeutic benefit, and responses differ widely in magnitude and duration. In this study, we evaluated whether differences in the AR cistrome before treatment can distinguish between SPT-responding (R) and -nonresponding (NR) tumors. We provide the first preclinical evidence to our knowledge that SPT-R tumors exhibit a distinct AR cistrome when compared with SPT-NR tumors, indicating a different","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2026-03-31T11:54:27.256Z","creation":"2025-04-20T03:06:54.892Z"},"accession":"S-EPMC9220831","cross_references":{"pubmed":["35603787"],"doi":["10.1172/jci.insight.157164"]}}